113 related articles for article (PubMed ID: 8625541)
1. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins.
Dodd RY
Clin Exp Immunol; 1996 May; 104 Suppl 1():31-4. PubMed ID: 8625541
[TBL] [Abstract][Full Text] [Related]
2. The viral safety of intravenous immune globulin.
Yap PL
Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
[TBL] [Abstract][Full Text] [Related]
3. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
4. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
[TBL] [Abstract][Full Text] [Related]
5. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
[TBL] [Abstract][Full Text] [Related]
6. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
7. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
Owusu-Ofori S; Temple J; Sarkodie F; Anokwa M; Candotti D; Allain JP
Transfusion; 2005 Feb; 45(2):133-40. PubMed ID: 15660820
[TBL] [Abstract][Full Text] [Related]
8. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
Busch MP
Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.
O'Brien SF; Fearon MA; Yi QL; Fan W; Scalia V; Muntz IR; Vamvakas EC
Transfusion; 2007 Oct; 47(10):1809-15. PubMed ID: 17880605
[TBL] [Abstract][Full Text] [Related]
10. Will genome detection replace serology in blood screening for microbial agents?
Allain JP
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):615-29. PubMed ID: 11102280
[TBL] [Abstract][Full Text] [Related]
11. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
[TBL] [Abstract][Full Text] [Related]
12. Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil.
Maresch C; Schluter PJ; Wilson AD; Sleigh A
Transfusion; 2008 Feb; 48(2):273-81. PubMed ID: 18005323
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007.
Kafi-abad SA; Rezvan H; Abolghasemi H; Talebian A
Transfusion; 2009 Oct; 49(10):2214-20. PubMed ID: 19527477
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
Kleinman SH; Strong DM; Tegtmeier GG; Holland PV; Gorlin JB; Cousins C; Chiacchierini RP; Pietrelli LA
Transfusion; 2005 Aug; 45(8):1247-57. PubMed ID: 16078909
[TBL] [Abstract][Full Text] [Related]
15. Occult hepatitis B virus infection: implications in transfusion.
Allain JP
Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
[TBL] [Abstract][Full Text] [Related]
16. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.
Gonzalez M; Règine V; Piccinini V; Vulcano F; Giampaolo A; Hassan HJ
Transfusion; 2005 Oct; 45(10):1670-5. PubMed ID: 16181219
[TBL] [Abstract][Full Text] [Related]
17. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
18. [Plasma donor screening and product safety].
Storch H; Ponsel G; Igel H; Worofka R
Beitr Infusionsther Transfusionsmed; 1997; 34():31-6. PubMed ID: 9417350
[TBL] [Abstract][Full Text] [Related]
19. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations.
Bamaga MS; Bokhari FF; Aboud AM; Al-Malki M; Alenzi FQ
Saudi Med J; 2006 Jun; 27(6):781-7. PubMed ID: 16758035
[TBL] [Abstract][Full Text] [Related]
20. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
Seed CR; Kiely P; Keller AJ
Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
